Generation of HPV-16 H-2 Kb-restricted E6 Peptide (aa 48-57)-specific CD8+ T Cell Line

Case ID:
C14309
Disclosure Date:
7/28/2016
Description:

ABSTRACT

The HPV-16 E6-specific CD8+ T cell line is generated by vaccinating six to eight week old female C57BL/6 (H2-Kb) mice with 2ug of pcDNA3-CRT/E6 using a helium-driven gene gun. Mice received two boosts with the same regimen 1 and 2 weeks later. The resulted splenocytes were harvested, stimulated with irradiated TC-1 tumor cells in the presence of murine IL-2 (20U/ml) for eight weeks, and sorted for E6-specificity and CD8 expression. The resulted E6-specific CD8+ T cell recognizes the HPV-E6 epitope (amino acid 48-57).
 

FEATURES

The resulted E6-specific CD8+ T cell recognizes the HPV-E6 epitope (amino acid 48-57). These T cells can be used to assess HPV-16 E6 processing and presentation and be used to assess DNA vaccines encoding the HPV-16 E6 antigen and whether it can elicit enhanced E6-specific CD8+ T-cell immune responses and antitumor effects in preclinical studies.


STAGE OF DEVELOPMENT

E6 peptide (aa 48-57)-specific CD8+ T cells were characterized by determining the ability of T cells to kill HPV-16 E6 (aa 48-57) peptide-pulsed EL-4 cells and by staining for CD8.


ASSOCIATED PUBLICATIONS

J Virol. 2004 Aug;78(16):8468-76.

Patent Information:
Inventors:
Category(s):
For Information, Contact:
Christine Joseph
cjoseph6@jhmi.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum